Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 19/20 | 0.80 |
| ▸ | EGFR | P00533 | 1/20 | 0.78 |
| ▸ | INSR | P06213 | 1/20 | 0.74 |
| ▸ | IGF1R | P08069 | 1/20 | 0.74 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16385429 | 0.92 | ALK (0.80) | ALKEGFRINSRIGF1R | |
| SCHEMBL30682433 | 0.91 | ALK (0.84) | ALKINSRIGF1RMAPK3 | |
| SCHEMBL16372102 | 0.91 | ALK (0.77) | ALKEGFRINSRIGF1RMAPK3 | |
| SCHEMBL16385431 | 0.89 | ALK (0.81) | ALKMAPK3 | |
| SCHEMBL16372231 | 0.89 | ALK (0.75) | ALKINSRIGF1RMAPK3 | |
| SCHEMBL16769540 | 0.89 | ALK (1.00) | ALK | |
| SCHEMBL16371689 | 0.89 | ALK (0.74) | ALKEGFRINSRIGF1RMAPK3 | |
| SCHEMBL16371803 | 0.88 | ALK (1.00) | ALKEGFRINSRIGF1R | |
| SCHEMBL16752884 | 0.87 | ALK (1.00) | ALK | |
| SCHEMBL16752903 | 0.87 | ALK (1.00) | ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145237-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-05-26 | — | — | US | claimed |
| EP-3019489-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | Betta Pharmaceuticals Co., Ltd. (CN) | 2016-05-18 | — | — | EP | claimed |
| WO-2015003658-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2015-01-15 | — | — | WO | claimed |
| US-10059688-B2 | Protein tyrosine kinase modulators and methods of use | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2018-08-28 | — | — | US | disclosed |
| US-20180009782-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2018-01-11 | — | — | US | disclosed |
| US-20180009782-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2018-01-11 | — | — | US | disclosed |
| US-9783524-B2 | Protein tyrosine kinase modulators and methods of use | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2017-10-10 | — | — | US | disclosed |
| US-9783524-B2 | Protein tyrosine kinase modulators and methods of use | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2017-10-10 | — | — | US | disclosed |
| US-9783524-B2 | Protein tyrosine kinase modulators and methods of use | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2017-10-10 | — | — | US | disclosed |
| US-20160145237-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-05-26 | — | — | US | disclosed |
| US-20160145237-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-05-26 | — | — | US | disclosed |
| US-20160145237-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-05-26 | — | — | US | disclosed |
| WO-2015003658-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145237-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | ALK, EGFR, ERBB2 | ALK 1/4885EGFR 2/4885INSR 1250/4885 |
| US-10059688-B2 | Protein tyrosine kinase modulators and methods of use | ALK, EGFR, ERBB2 | ALK 1/4885EGFR 2/4885INSR 1250/4885 |
| US-20180009782-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | ALK, EGFR, ERBB2 | ALK 1/4885EGFR 2/4885INSR 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.